Duyuru • May 16
CBD Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $0.448 million. CBD Life Sciences Inc. has filed a Follow-on Equity Offering in the amount of $0.448 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,000,000,000
Price\Range: $0.000112
Discount Per Security: $0 Duyuru • Jan 07
CBD Life Sciences, Inc. Secures Breakthrough Walmart Marketplace Approval for Mushroom Supplement, Setting the Stage for Unprecedented Growth CBD Life Sciences Inc. announce that its Mushroom Madness Rise Gummies, featuring a powerful Lion's Mane mushroom blend, have officially been approved for sale and are now available on Walmart Marketplace. This monumental approval opens the door for CBDL to tap into Walmart's expansive e-commerce ecosystem, providing a pathway to substantial revenue growth while strengthening its position in the rapidly expanding functional mushroom market. The global functional mushroom market continues to surge, projected to reach $42.4 billion by 2028, with Lion's Mane products leading the charge due to their cognitive health benefits. CBDL's Mushroom Madness Rise Gummies, formulated for focus, clarity, and enhanced mental performance, are well-positioned to meet the increasing demand for natural wellness solutions. Walmart Marketplace, recognized as one of the fastest-growing online retail platforms, boasts over 100 million monthly visitors. With third-party sellers generating substantial portions of Walmart's e-commerce revenue, the platform offers unmatched scalability and visibility for emerging brands. CBDL's entry onto Walmart Marketplace provides logistical efficiencies, enhanced consumer trust, and a direct line to an enormous, ever-expanding customer base. Industry reports indicate that third-party sellers often experience double-digit sales growth within months of launching on Walmart Marketplace. This offers CBDL an unprecedented opportunity to scale its revenues rapidly, further bolstered by Walmart's robust digital marketing support and fulfillment network. CBD Life Sciences has already achieved impressive financial growth, recording a 1405.46% increase in revenue since February 2024. The company expects Walmart Marketplace to significantly enhance its revenue stream, given the rapid consumer adoption of functional mushroom products and CBD-infused supplements. The Mushroom Madness Rise Gummies are a strategic addition to CBDL's product lineup, aligning with the company's commitment to offering scientifically formulated, high-efficacy wellness products. These gummies not only serve a growing wellness market but also position CBDL to capture a significant share of the $20 billion U.S. supplement industry. As part of its long-term strategy, CBDL plans to launch additional top-selling products on Walmart Marketplace, including its highly anticipated nano-CBD supplements and mushroom-enhanced nutritional powders. Duyuru • Dec 03
CBD Life Sciences Inc. Announces New Delta-8 100MG Gummies Designed to Support Individuals Living with Alzheimer's CBD Life Sciences Inc. announced the launch of its groundbreaking Delta-8 100mg Gummies, specially formulated to support individuals living with Alzheimer's disease. These expertly crafted gummies offer gentle relief and enhanced well-being, addressing the unique needs of patients and their families navigating the challenges of neurodegenerative conditions. CBD Life Sciences' entry into this specialized segment of the $6 billion U.S. edibles market positions the company as a pioneer in creating products tailored to an underserved demographic. As the population ages and awareness of natural alternatives grows, Delta-8 products are rapidly gaining traction as effective solutions for managing symptoms associated with Alzheimer's and related conditions. A Product Born from Real Needs and Scientific Innovation: The development of these gummies is deeply rooted in the stories of CBD Life Sciences' clients, who shared how Delta-8 products have positively impacted their loved ones living with Alzheimer's. This heartfelt feedback spurred the creation of a product aimed at addressing symptoms such as anxiety, restlessness, agitation, and mood swings, all while promoting cognitive calmness and overall quality of life.Delta-8, a naturally occurring cannabinoid, is celebrated for its mild yet effective benefits. Unlike more aggressive treatments, Delta-8 provides a balance of support without overwhelming psychoactive effects, making it an ideal choice for seniors seeking natural relief. Revenue and Growth Potential: The Alzheimer's population in the United States is expected to exceed 12.7 million by 2050, creating a significant and growing demand for targeted wellness products. Early projections indicate that this product line could contribute an additional $3 million in revenue within its first year, as CBD Life Sciences continues to meet the rising interest in cannabinoid-based solutions for elderly care. The senior segment of the edibles market is rapidly emerging as a key growth area. A recent study reported a 300% increase in cannabinoid use among individuals aged 65 and older over the past decade. This demographic is increasingly turning to natural products like Delta-8 for their ability to support physical and cognitive health without the side effects often associated with pharmaceuticals. Meeting the Needs of an Underserved Market: CBD Life Sciences'Delta-8 Gummies are designed with seniors in mind. These gummies are made from all-natural ingredients, offering easy consumption, precise dosing, and a discreet form factor. Rigorous third-party testing ensures their purity, potency, and consistency, providing families and caregivers with confidence in their safety and efficacy. The gummies' formulation emphasizes cognitive support and emotional balance, helping to manage the everyday challenges of Alzheimer's while offering peace of mind to those providing care. CBD Life Sciences: Setting the Standard in Innovation: The launch of the Delta-8 Gummies for Alzheimer's marks another milestone in CBD Life Sciences' remarkable growth trajectory. Since February 2024, the company has achieved a 1405.46% increase in revenue, driven by its commitment to delivering high-quality, innovative products that resonate with consumers. This latest product also highlights the company's strategic focus on expanding its reach in the health and wellness sector, where demand for cannabinoid-based solutions continues to skyrocket. By addressing the specific needs of aging individuals and their families, CBD Life Sciences solidifies its position as a trusted leader in the industry. Duyuru • Nov 02
CBD Life Sciences Inc. Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into A Booming $20 Billion Market CBD Life Sciences Inc. sets a new industry standard with its launch of a high-performance line of mushroom-infused gummies, designed to meet the surging demand for wellness products in a projected $20 billion market. Focused on energy, sleep, and sexual wellness, these unique formulations offer CBDL shareholders and new investors an unprecedented growth opportunity in an exploration sector. With an expanding consumer focus on holistic health and functional ingredients, CBDL's Rise, Dream, and Bloom Gummies each bring targeted benefits, including cognitive enhancement, restful sleep, and boosted vitality. These products are strategically positioned to address top wellness priorities, blending potent natural ingredients with advanced formulation technology. This launch is expected to significantly contribute to CBDL's revenue stream, enhancing shareholder value and setting the company apart as an innovator in functional wellness. Rise Gummies are formulated to support focus and energy, each containing 500mg of Lion's Mane Mushroom, 1 microgram of B12, and 25mg of Ginseng. This combination aligns with a growing segment of consumers seeking natural solutions to boost mental clarity and productivity. Dream Gummies provide natural support for relaxation and sleep, with 500mg of Reishi Mushroom, 25mg of Kava, and 10mg of 5-HTP. With sleep wellness now a top priority for many, Dream Gummies offer a non-habit-forming solution to support stress relief and emotional balance. Bloom Gummies offer a targeted formula for sexual wellness and vitality, incorporating 500mg of Cordyceps Mushroom along with Tongkat Ali, Ginkgo Biloba, Ginseng, L-Arginine, Ashwagandha, and Maca. With its pioneering approach to wellness, CBDL is dedicated to securing sustained value for investors by remaining at the forefront of natural health innovation. Duyuru • Oct 03
CBD Life Sciences, Inc. Launches CBD Horse Paste CBD Life Sciences Inc. announced the launch of its latest product, the CBD Horse Paste. This veterinarian-designed formulation is the first of its kind, offering unparalleled support for horses facing both physical and psychological challenges. Equine health concerns such as muscle stiffness, joint pain, and anxiety can significantly affect a horse's well-being. The CBD Horse Paste addresses these issues with a unique combination of cannabinoids and terpenes, providing an easy-to-administer solution that stays in the horse's mouth longer than CBD oils, ensuring maximum absorption. Each syringe delivers 500mg of premium CBD with a flavor horses love, making it ideal for stress-inducing situations like farrier visits or long trailer rides. Key Benefits of CBD Horse Paste: Veterinarian-Designed Formulation: Created by equine health experts for maximum effectiveness. Comprehensive Health Support: Eases muscle stiffness, joint issues, and stress-related behaviors like boredom and anxiety. Easy-to-Use: Each syringe contains four doses, making it convenient for horse owners. Delicious Flavor: The paste's flavor ensures horses readily accept it. Versatile Application: Perfect for use during stressful situations, such as travel, farrier visits, and training sessions. Innovative CBD for Equine Wellness: The CBD Horse Paste not only addresses common equine health concerns but also serves as a natural alternative to traditional calming agents and medications. By leveraging the powerful properties of CBD and terpenes, horses can experience relief from arthritis-induced stiffness and joint pain, as well as a reduction in anxiety caused by environmental changes, isolation, or past trauma. Duyuru • Sep 24
CBD Life Sciences, Inc. Announces Expanding Revenue Stream with Walmart Marketplace CBD Life Sciences Inc. announced the launch of its product line on Walmart Marketplace. This milestone marks a significant leap in retail strategy, poised to drive substantial revenue growth and expand market reach to millions of potential customers. Market Expansion: By entering the Walmart Marketplace, the company are now accessible to one of the largest retail platforms in the world, boasting over 120 million monthly visitors. This launch strategically positions CBDL to significantly increase brand visibility and consumer base. Revenue Growth: Early forecasts project a substantial revenue boost, with a projected increase of 35% in annual sales due to this new distribution channel. The company revenue growth over the past 12 months has already seen a 20% rise, and the company expects accelerated growth driven by this expansion. Product Line on Walmart: The initial offerings will include top-selling Nano CBD Coffee Creamer, Mellow Mornings, and CBD Pain Cream, which have seen growing demand in local markets. These products, praised for their effectiveness, will now have national distribution, broadening customer base across the U.S. Investor Impact: This move opens additional streams of revenue that will enhance shareholder value. By diversifying sales channels, the company aim to increase its gross margins by 10% while driving stronger returns for investors over the next fiscal year. A Proven Path to Growth: As a small but rapidly growing company, the company recognize that entering high-traffic marketplaces like Walmart is a powerful catalyst for scaling. The company continue to prioritize innovation in product lines and have seen positive feedback from both consumers and local retailers. With products now on Walmart Marketplace, the company anticipates a robust competitive edge and a much larger footprint in the booming CBD sector, which is projected to reach $47.22 billion by 2028. 